Scaling Network Medicine with LLMs for Combinatorial Drug Repurposing in ER+ Breast Cancer
Drug repurposing can accelerate therapy discovery for ER+ breast cancer, but combination selection remains difficult. We developed an LLM-driven network medicine framework that extracts drug--target relationships from 595,122 PubMed abstracts, builds a cross-model consensus network, overlays it onto the KEGG estrogen signaling pathway, and enumerates complementary drug pairs. Candidate…
We haven't written up this one. bioRxiv has the full story — the link below goes straight to it.
